Disappointing subgroup results for OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals Inc. (Nasdaq: OGXI) reported that a subpopulation of men in a Phase 3 AFFINITY trial with custirsen experienced no improvement sending the stock price tumbling 99 cents to close at $1.63.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.